ASCO 2022: T-DXd in HER2-Low Unresectable and/or Metastatic Breast Cancer

Posted: 06/05/2022 | By: Chase Doyle

Question 1 of 5

Patients with HR-negative disease randomly assigned to receive T-DXd had a median progression-free survival of how many months?

Choose 1